Literature DB >> 22037257

Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.

So Yeon Park1, Hyeong Ju Kwon, Yoomi Choi, Hee Eun Lee, Sung-Won Kim, Jee Hyun Kim, In Ah Kim, Namhee Jung, Nam-Yun Cho, Gyeong Hoon Kang.   

Abstract

Although DNA methylation profiles in breast cancer have been connected to breast cancer molecular subtype, there have been no studies of the association of DNA methylation with stem cell phenotype. This study was designed to evaluate the promoter CpG island methylation of 15 genes in relation to breast cancer subtype, and to investigate whether the patterns of CpG island methylation in each subtype are associated with their cancer stem cell phenotype represented by CD44+/CD24- and ALDH1 expression. We performed MethyLight analysis of the methylation status of 15 promoter CpG island loci involved in breast cancer progression (APC, DLEC1, GRIN2B, GSTP1, HOXA1, HOXA10, IGF2, MT1G, RARB, RASSF1A, RUNX3, SCGB3A1, SFRP1, SFRP4, and TMEFF2) and determined cancer stem cell phenotype by CD44/CD24 and ALDH1 immunohistochemistry in 36 luminal A, 33 luminal B, 30 luminal-HER2, 40 HER2 enriched, and 40 basal-like subtypes of breast cancer. The number of CpG island loci methylated differed significantly between subtypes, and was highest in the luminal-HER2 subtype and lowest in the basal-like subtype. Methylation frequencies and levels in 12 of the 15 genes differed significantly between subtypes, and the basal-like subtype had significantly lower methylation frequencies and levels in nine of the genes than the other subtypes. CD44+/CD24- and ALDH1+ putative stem cell populations were most enriched in the basal-like subtype. Methylation of promoter CpG islands was significantly lower in CD44+/CD24-cell (+) tumors than in CD44+/CD24-cell (-) tumors, even within the basal-like subtype. ALDH1 (+) tumors were also less methylated than ALDH1 (-) tumors. Our findings showed that promoter CpG island methylation was different in relation to breast cancer subtype and stem cell phenotype of tumor, suggesting that breast cancers have distinct patterns of CpG island methylation according to molecular subtypes and these are associated with different stem cell phenotypes of the tumor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037257     DOI: 10.1038/modpathol.2011.160

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  25 in total

1.  Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis.

Authors:  Denise K Reaves; Katherine A Hoadley; Katerina D Fagan-Solis; Dereje D Jima; Michael Bereman; Lynnelle Thorpe; Jyla Hicks; David McDonald; Melissa A Troester; Charles M Perou; Jodie M Fleming
Journal:  Mol Cancer Res       Date:  2016-11-17       Impact factor: 5.852

Review 2.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

3.  Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.

Authors:  Paola Marcato; Cheryl A Dean; Rong-Zong Liu; Krysta M Coyle; Moamen Bydoun; Melissa Wallace; Derek Clements; Colin Turner; Edward G Mathenge; Shashi A Gujar; Carman A Giacomantonio; John R Mackey; Roseline Godbout; Patrick W K Lee
Journal:  Mol Oncol       Date:  2014-07-24       Impact factor: 6.603

4.  Identification of HOXA1 as a Novel Biomarker in Prognosis of Head and Neck Squamous Cell Carcinoma.

Authors:  Hui Li; Xiaomin Wang; Mingjie Zhang; Mengjun Wang; Junjie Zhang; Shiyin Ma
Journal:  Front Mol Biosci       Date:  2021-03-08

Review 5.  DNA methylation signatures for breast cancer classification and prognosis.

Authors:  Moshe Szyf
Journal:  Genome Med       Date:  2012-03-30       Impact factor: 11.117

Review 6.  Regulation of breast cancer stem cell features.

Authors:  Patrycja Czerwinska; Bozena Kaminska
Journal:  Contemp Oncol (Pozn)       Date:  2015

7.  The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.

Authors:  Heloisa Helena Milioli; Renato Vimieiro; Carlos Riveros; Inna Tishchenko; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

Review 8.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.

Authors:  Shuji Ogino; Paul Lochhead; Andrew T Chan; Reiko Nishihara; Eunyoung Cho; Brian M Wolpin; Jeffrey A Meyerhardt; Alexander Meissner; Eva S Schernhammer; Charles S Fuchs; Edward Giovannucci
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842

9.  Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.

Authors:  Khalid Abubaker; Ardian Latifi; Rod Luwor; Simon Nazaretian; Hongjian Zhu; Michael A Quinn; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed
Journal:  Mol Cancer       Date:  2013-03-27       Impact factor: 27.401

10.  DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.

Authors:  Kathleen Conway; Sharon N Edmiston; Ryan May; Pei Fen Kuan; Haitao Chu; Christopher Bryant; Chiu-Kit Tse; Theresa Swift-Scanlan; Joseph Geradts; Melissa A Troester; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2014-10-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.